设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2020 年第 11 期 第 15 卷

孟鲁司特钠片联合布地奈德混悬液治疗支气管哮喘的效果及对患者气道炎症反应的影响

The effect and its influence on airway inflammation in patients of montelukast combined with budesonide in the treatment of bronchial asthma

作者:孙晓丽张湘华曹晓玮

英文作者:Sun Xiaoli Zhang Xianghua Cao Xiaowei

单位:石家庄市第一医院呼吸科050000

英文单位:Department of Respiration Shijiazhuang No.1 Hospital Shijiazhuang 050000 China

关键词:支气管哮喘;孟鲁司特;布地奈德;嗜酸粒细胞阳离子蛋白;脂质过氧化物;呼出气一氧化

英文关键词:Bronchialasthma;Montelukast;Budesonide;Eosinophilcationicprotein;Lipidperoxide;Fractionalexhalednitricoxide

  • 摘要:
  • 目的 探讨孟鲁司特钠片联合布地奈德混悬液治疗支气管哮喘的效果及对患者血清嗜酸粒细胞阳离子蛋白(ECP)、脂质过氧化物(LPO)、呼出气一氧化氮(FeNO)表达的影响。方法 选取20171月至20196月石家庄市第一医院收治的91例支气管哮喘患者为研究对象,按照随机数字表法分为对照组(45例)和观察组(46例)。在常规治疗基础上,对照组给予布地奈德混悬液2 ml+3 ml 0.9%氯化钠注射液雾化吸入治疗,15 min/次,2/d;观察组在对照组基础上给予孟鲁司特钠片10 mg/次,1/d口服治疗。比较2组临床疗效,咳嗽缓解时间、胸闷缓解时间、肺部哮鸣音消失时间、喘息缓解时间,治疗前后血清ECPLPOFeNO表达水平和不良反应发生率。结果 治疗后,观察组治疗有效率明显高于对照组[93.5%43/46)比77.8%35/45)],咳嗽缓解时间、胸闷缓解时间、肺部哮鸣音消失时间、喘息缓解时间均明显短于对照组[(4.7±1.0d比(5.7±1.3d、(4.6±1.1d比(5.8±1.3d、(5.2±1.3d比(6.6±1.3d、(3.8±1.4d比(4.7±1.3d],差异均有统计学意义(均P0.05)。治疗后,2组血清ECPLPOFeNO表达含量均低于治疗前,且观察组均低于对照组,差异均有统计学意义(均P0.05)。2组皮疹、恶心、声嘶、头痛、咽喉不适等不良反应发生率比较差异均无统计学意义(均P0.05)。结论 孟鲁司特钠片联合布地奈德混悬液能够提高支气管哮喘的治疗效果,促进症状改善,减轻气道炎症反应,降低血清ECPLPOFeNO表达水平,且不会增加不良反应。

  • Objective To investigate the therapeutic effect of montelukast sodium combined with budesonide suspension and its effect on bronchial asthma, eosinophil cationic protein (ECP), lipid peroxide (LPO) and fractional exhaled nitric oxide (FeNO). Methods Totally 91 patients with bronchial asthma admitted to Shijiazhuang No.1 Hospital from January 2017 to June 2019 were selected. According to the random number table method, the patients were divided into control group (45 cases) and observation group (46 cases). On the basis of routine treatment, the control group was given budesonide suspension 2 ml + 0.9% saline 3 ml atomization inhalation, 15 min/timetwice a day; the observation group was given montelukast sodium tablets 10 mg/time, once a day, on the basis of the control group. The clinical efficacy, the cough relief time, chest distress relief time, lung chirp disappearance time, wheeze relief time, serum ECP, LPO and FeNO levels and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group93.5%43/46 vs 77.8%35/45)]; after treatment, the cough relief time, chest distress relief time, lung murmur disappearance time and wheeze relief time of the observation group were shorter than those of the control group[(4.7±1.0d vs 5.7±1.3d, 4.6±1.1d vs 5.8±1.3d,5.2±1.3d vs 6.6±1.3d, 3.8±1.4d vs 4.7±1.3d(all P0.05). After treatment, the levels of serum ECP, LPO and FeNO in the two groups were lower than those before treatment; the levels of observation group were lower than those of control group(all P0.05). There was no significant difference in the incidence of rash, nausea, hoarseness, headache and throat discomfort between the two groups (all P0.05). ConclusionThe combination of montelukast sodium tablets and budesonide suspension can improve the curative effect of bronchial asthma, promote the improvement of symptoms, reduce airway inflammation, reduce the expression levels of serum ECP, LPO and FeNO, and does not increase the adverse reactions.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭